A patent review of histone deacetylase 8 (HDAC8) inhibitors (2013-present)

ABSTRACT

Introduction

The processes and course of several fatal illnesses, such as cancer, inflammatory diseases, and neurological disorders, are closely correlated with HDAC8. Therefore, novel HDAC8 inhibitors represent effective therapeutic possibilities that may help treat these conditions. To yet, there aren’t any such particular HDAC8 inhibitors available for sale. This review was conducted to examine recent HDAC8 inhibitors that have been patented over the last ten years.

Areas covered

This review focuses on HDAC8 inhibitor-related patents and their therapeutic applications that have been published within the last ten years and are accessible through the Patentscope and Google Patents databases.

Expert opinion

A handful of HDAC8 inhibitor-related patents have been submitted over the previous ten years, more selective, and specific HDAC8 inhibitors that are intended to treat a variety of medical diseases. This could lead to the development of novel treatment approaches that target HDAC8. Employing theoretical frameworks and experimental procedures can reveal the creation of new HDAC8 inhibitors with enhanced pharmacokinetic characteristics. A thorough understanding of the role that HDAC8 inhibitors play in cancer including the mechanisms behind HDAC8 in other disorders is necessary.

KEYWORDS:

• HDAC8
• cancer
• HDAC8 inhibitor
• clinical trials
• modified fish-like structure
• hydroxamates
• non-hydroxamates

Disclaimer

As a service to authors and researchers we are providing this version of an accepted manuscript (AM). Copyediting, typesetting, and review of the resulting proofs will be undertaken on this manuscript before final publication of the Version of Record (VoR). During production and pre-press, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal relate to these versions also.

Article highlights

• HDAC8 is a promising target for drug development against cancer, inflammatory diseases, and neurological disorders.

• No such specific HDAC8 inhibitor is available in clinics to date.

• Several effective HDAC8 inhibitors have been patented for the last decade.

• Modified fish-like molecular structures are crucial for selective HDAC8 inhibition.

• Novel and selective HDAC8 inhibitors can explore promising clinical outcomes against various life-threatening diseases.

Declaration of interests

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Author contribution statement

S. Banerjee contributed toward the drafting, gathering patent-related information, and finalization of the manuscript. B. Ghosh and T. Jha contributed to the editing, reviewing, and finalization of the manuscript. N. Adhikari conceptualized the current idea, gathered patent-related information, supervised, edited, reviewed, and contributed to the final framework of the article. All authors have approved the final version of the manuscript.

Data availability statement

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

Additional information

Funding

This paper was funded by the Swami Vivekananda Merit-cum-Means (SVMCM) scholarship, Govt. of West Bengal, India, and the authority of Jadavpur University.